Abstract 37P
Background
The "Hallmarks of Cancer" framework is foundational for understanding common organizational principles underlying diverse cancer types. However, the absence of a consensus gene set for cancer hallmarks leads to varied biological interpretations across studies. In this work, we established a unified cancer hallmark gene set by merging data from existing mapping resources and devising a framework for gene set mining.
Methods
We searched the NCBI PubMed database for publications from which a list of cancer hallmark genes could be extracted or reconstructed. Then, we performed a cancer hallmarks enrichment analysis on a list of differentially expressed genes between normal and tumor tissues across eleven solid tumor types.
Results
Consolidating hallmark genes from seven projects, we identified 6,763 genes associated with ten cancer hallmarks. We discovered a hallmark enrichment “fingerprint” specific to each tumor type. Notably, kidney cancers displayed the most extensive hallmark enrichment, underscoring the complexity of the disease. Hallmarks linked to immune function, such as “Evading immune destruction” and “Tumor promoting inflammation” were prominently enriched in kidney and CNS cancers (p<0.0001). “Tissue invasion and metastasis” was the single most prominent hallmark in skin and pancreatic cancers (p<0.0001), known to metastasize early. "Reprogramming energy metabolism" emerged as the hallmark particularly enriched in breast, ovarian, and uterine cancers (p<0.0001), suggesting the feasibility of metabolic approaches to target these cancers. The hallmark “Genome instability” was significantly enriched in cancers frequently associated with lifestyle choices, including colon, oesophageal, and liver cancers (p<0.05), and in cervical cancers, known to be linked to HPV infection (p<0.0001). To facilitate the analysis of cancer hallmarks, we developed an online tool (www.cancerhallmarks.com) to identify cancer-associated hallmarks from novel gene sets.
Conclusions
We established a consensus list of cancer hallmark genes and delineated unique patterns of hallmark enrichment across diverse tumors. Our findings hold potential pharmacological implications and enhance the utility of the hallmark concept as an effective organizational tool.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This project was supported by the National Research, Development, and Innovation Office (PharmaLab, RRF-2.3.1-21-2022-00015) in Hungary. O.M. was supported by the Janos Bolyai Scholarship of the Hungarian Academy of Sciences and the Hungarian Scientific Research Fund (OTKA FK147194). The support of ELIXIR Hungary (www.bioinformatics.hu) is acknowledged.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
10P - Multivariate analysis of functional organoid assays predicts patient responses in the clinic for colorectal and pancreatic cancer
Presenter: Anna-Rose Gryspeert
Session: Poster session 07
11P - Therapeutic effects of MRTX1133 in KRAS G12D mutant appendiceal cancer: Insights from organoid and in vivo studies
Presenter: John Paul Shen
Session: Poster session 07
12P - STING-activable pyroptotic nanoparticles deliver GSDMDNT mRNA for in situ pancreatic cancer vaccination and immunotherapy
Presenter: Shiyi Shao
Session: Poster session 07
Resources:
Abstract
14P - EED inhibition renders vulnerability to immunotherapy by rewiring ceramide metabolism in pancreatic cancer
Presenter: Fan Chen
Session: Poster session 07
15P - TIGIT+ CD8+ T cells limit the efficacy of PD-L1 blockade plus chemoradiotherapy in MSS locally advanced rectal cancer via NECTIN2-TIGIT interplay
Presenter: Zhehui Zhu
Session: Poster session 07
16P - PTEN deficiency leads to colorectal cancer immune evasion via atypical Keap1/Nrf2 pathway
Presenter: RunKai Cai
Session: Poster session 07
17P - Breaking chemotherapy resistance in gastric adenocarcinoma: Immunogenic cell death induction by carbonic anhydrase IX targeting
Presenter: Elena Andreucci
Session: Poster session 07
18P - The role of CTNNA1 truncating variants in hereditary diffuse gastric cancer (HDGC)
Presenter: Silvana Lobo
Session: Poster session 07
19P - KSR1 as a therapeutic target for hepatocellular carcinoma with activated RAS-RAF-MEK-ERK signaling pathway
Presenter: HYUK MOON
Session: Poster session 07
20P - Preclinical characterization of FGFR1-4 variants of unknown significance
Presenter: Martin Ziegler
Session: Poster session 07